Prevention of treatment-induced ototoxicity: An update for clinicians by Ramma, L et al.
145       March 2019, Vol. 109, No. 3
CME
Unwanted adverse effects from drugs as part of medical treatment 
are common.[1] It is therefore as important for clinicians to recognise 
adverse drug reactions (ADRs) as it is to diagnose serious diseases 
if effective clinical management is to be realised.[2] Ototoxicity is an 
adverse reaction resulting from the pharmacological treatment of 
many life-threatening illnesses, such as cancer, multidrug-resistant 
tuberculosis and congestive heart failure,[2] and it is increasingly 
becoming a problem in low- and middle-income countries (LMICs) 
such as South Africa (SA). Some ototoxic medicines primarily 
affect the auditory system (cochleotoxic), while others primarily 
affect the vestibular system (vestibulotoxic), and some classes, e.g. 
aminoglycosides, affect both systems.[3]
The reported incidence of ototoxic side-effects varies extensively 
depending on several variables: drug type, classification criteria for 
ototoxicity and patients’ demographic profiles. The incidence ranges 
from 18% (for some aminoglycosides) to 100% (for some platinum 
compounds, e.g. cisplatin).[4,5] There is considerable variation in 
individual susceptibility to drug-induced ototoxicity. Table 1 provides 
a list of some of the risk factors associated with ototoxicity and 
primarily focuses on commonly prescribed drugs, such as the 
aminoglycosides, chemotherapeutic agents and loop diuretics.[6,7]
The onset of ototoxicity symptoms varies from a few days to 
months after systemic administration.[8] Ototoxicity may present 
as cochleotoxicity or vestibulotoxicity or both. Cochleotoxicity 
may exhibit hearing loss, which could be permanent, tinnitus or 
hyperacusis (increased sensitivity to everyday sounds), as well as 
difficulty with speech discrimination, especially in the presence 
of background noise. Vestibulotoxicity may present as general 
disequilibrium, unsteadiness when walking or ataxic gait, oscillopsia 
and nystagmus.[8,9]
Iatrogenic hearing loss resulting from ototoxicity can have a 
negative impact on affected individuals. Patients may experience 
communication difficulties, which could lead to isolation, depression 
and diminishing integration in a wider society.[10] Likewise, loss 
of vestibular function due to ototoxicity can impair one’s ability to 
perform activities of daily living and integration within society, thus 
resulting in depression, cognitive decline and diminished quality of 
life.[11] 
Treatment regimens that include ototoxic pharmacological agents 
require clinicians to navigate the delicate balance of remedying the 
primary health condition and ensuring that the patient’s hearing 
and vestibular status are not negatively affected. Fortunately, 
improvements in pharmacological management of patients who are 
treated with such regimens now present clinicians with more options 
to prevent ototoxicity. Therefore, patients should not be burdened 
with the task of making the unenviable choice of ‘death or deaf ’. 
Physicians should explore all the available options for preventing 
treatment-induced ototoxicity. 
Ototoxic medicines
Many medicines are known to have some degree of ototoxic effect. 
While it is impossible for a clinician to remember all of these, 
certain drug classes such as the aminoglycosides and some platinum 
compounds are known to be associated with a higher incidence of 
ototoxicity – often with serious and irreversible consequences. Most 
recently, the newer generation of medicines, such as cyclodextrins 
(e.g. 2-hydroxypropyl-b-cyclodextrin (HPβCD)), have also been 
reported to be associated with some ototoxic effects.[12] Table 2 
presents an overview of some medicines with known ototoxic side-
effects. It is not an exhaustive list, but can serve as a quick reference. 
Prevention of pharmacotherapy-
induced ototoxicity
There is currently no phenotypic marker that can be used by 
clinicians to reliably predict the likelihood of developing ototoxicity 
after treatment. There is a paucity of evidence of the relationship 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Prevention of treatment-induced ototoxicity:  
An update for clinicians
L Ramma,1 AUD, MPH; N Schellack,2 BCur, BPharm, PhD; B Heinze,3 M(ECI), PhD  
1  Division of Communication Sciences and Disorders, Department of Health and Rehabilitation Sciences, Faculty of Health Sciences,  
University of Cape Town, South Africa
2 Department of Clinical Pharmacy, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa
3 Department of Speech-Language Pathology and Audiology, Faculty of Humanities, University of Pretoria, South Africa
Corresponding author: L Ramma (lebogang.ramma@uct.ac.za) 
Ototoxicity is a common side-effect during treatment of a a number of life-threatening health conditions. Often, when treating such 
conditions, the focus tends to be on saving the patient’s life rather than preserving their hearing or vestibular function. However, advances 
in clinical management of these conditions, availability of less ototoxic alternative medicines and developments in interventions to prevent 
ototoxicity now give clinicians a better opportunity to save the patient’s life and preserve their hearing and vestibular function. Effective 
communication between audiologists, clinical pharmacists and physicians is critical in preventing drug-induced ototoxicity. Clinicians 
need to stay up to date regarding scientific and clinical developments related to the prevention of treatment-induced ototoxicity. This article 
reviews common ototoxic medicinal agents and strategies to prevent ototoxicity, and discusses recent developments towards preventing 
drug-induced ototoxicity. 
S Afr Med J 2019;109(3):145-149. DOI:10.7196/SAMJ.2019.v109i3.13903
146       March 2019, Vol. 109, No. 3
CME
between ototoxicity, drug dosage, peak serum levels and renal toxicity.[14] 
Therefore, the only way to prevent pharmacotherapy-induced ototoxicity 
is to monitor patients during treatment. Cochleotoxicity monitoring 
involves prospective collection of serial audiometric data at regular 
intervals to ensure early detection of changes in hearing thresholds 
presumably attributed to the treatment regimen. Ototoxic damage 
typically starts in the cochlear base and progresses towards the 
apex. Hence, cochleotoxicity-monitoring protocols must include 
audiological tests that are sensitive to changes in ultra-high-frequency 
thresholds (i.e. test frequencies >8 kHz) and/or otoacoustic emissions.[15] 
It is important that baseline audiometric assessment is completed 
before administration of ototoxic medications. If this is not possible, 
baseline assessment should occur within 24 hours of cisplatin 
administration and within 72 hours of the initial treatment dose for 
aminoglycosides.[15] Symptoms of vestibulotoxicity (oscillopsia and 
disequilibrium) may be less obvious than the perception of tinnitus 
and hearing difficulties, especially if the patient is ill and bedridden, 
or may be attributed as being part of the illness. Considering that the 
semicircular canals are more susceptible to vestibulotoxicity than the 
otoliths, head impulse testing and dynamic visual acuity could be 
used to identify and monitor bilateral vestibular function.[11] 
Patients receiving ototoxic treatment should be monitored 
at regular intervals, which are medicine specific. Prevention of 
aminoglycoside-induced ototoxicity requires effective therapeutic 
drug monitoring, as well as hearing evaluation before, during and 
after drug treatment. Patients receiving platinum therapy should 
be evaluated prior to every cycle of chemotherapy. Additionally, 
monitoring should continue after treatment for at least 6 months 
(12 months for children ≤5 years old) to detect late-onset ototoxicity 
dysfunction.[15] 
Ototoxicity monitoring is premised on the fact that if a patient’s 
auditory and/or vestibular symptoms are detected early, the clinician 
has an opportunity to explore alternatives to treatment to prevent 
ototoxicity. These options may include replacing an ototoxic drug 
with a safer, less ototoxic one (where feasible) or changing the drug 
administration schedule (e.g. from daily dosage to 3 times per week) 
to reduce the concentration in the inner ear.[2]
The success of ototoxicity monitoring depends on effective 
communication between all health professionals involved in the 
management of patients who are being treated with ototoxic 
medicines (the clinical pharmacist, audiologist and doctor). Patients 
benefit the most if the information from these professionals regarding 
ototoxicity monitoring is communicated coherently and consistently. 
It is a duty of care for both the audiologist and the physician to ensure 
that auditory-vestibular information is communicated in a manner 
(or format) that enables the doctor to make a clinical decision to 
prevent further ototoxic damage. 
New developments in the prevention 
of ototoxicity
Some of the symptoms resulting from treatment with ototoxic 
medicines are irreversible and there is a need to protect patients from 
such effects. It is not always possible to prevent ototoxicity, even 
when patients are closely monitored during treatment. Because of 
this, alternative strategies are currently being developed and explored 
to work towards a future free of ototoxicity.[16] An obvious strategy 
is to discontinue the use of ototoxic medicines, thus eliminating 
the need for ototoxicity monitoring. However, some of the ototoxic 
medicines (e.g. cisplatin) are very effective therapeutic agents and 
therefore likely to remain in use until non-ototoxic alternatives 
become available. 
Alternative strategies are needed to eliminate or reduce ototoxicity. 
Three approaches currently receiving attention from researchers are: 
(i) development of efficacious otoprotective pharmacological agents; 
(ii) reversing ototoxicity-induced symptoms using neurotrophins; 
and (iii) identification of improved genetic markers that can be used 
to reliably identify patients at higher risk of developing ototoxicity. 
Pharmacological agents such as D-methionine have been shown to 
exhibit otoprotective benefits and therefore hold much potential.[17] 
Expression of certain neurotrophins in cochlear hair cells and neuro-
trophin receptors, selective tyrosine kinase receptor B (TrkB) and C 
(TrkC) and the low-affinity p75 receptor (a member of the tumour 
necrosis factor superfamily of receptors) in the spiral ganglion neu-
rons, has been revealed.[18]
Otoprotective agents can be aimed at protecting patients with 
normal auditory-vestibular function at the start of treatment, while 
neurotrophins can be an intervention that targets restoration.[16] 
Finally, identification of certain genetic markers via genetic screening 
Table 1. Risk factors and symptoms associated with ototoxicity 
Drug category Risk factors Symptoms 
Aminoglycosides Therapy lasting >7 days
Prior exposure to aminoglycosides
High daily doses
Age extremes (<5 years and >60 years)
Presence of specific mitochondrial mutations
Exposure to loud sounds
Dehydration
Prematurity
Permanent high-frequency sensorineural  
hearing loss
Oscillopsia and chronic dizziness/disequilibrium
Platinum compounds (i.e. cisplatin) Age extremes
Pre-existing hearing loss
Dose, duration and route of administration
Cranial irradiation
Concomitant use of other ototoxic agents
Dehydration
Permanent high-frequency sensorineural  
hearing loss 
High-pitched tinnitus
Loop diuretics Renal impairment 
Prematurity
Concomitant use of aminoglycoside antibiotic
Dehydration
Sudden progressive sensorineural  
hearing loss (flat configuration) – may be 
transient or permanent
Oscillopsia and chronic dizziness/disequilibrium 
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may facilitate easier identification of patients who are at higher risk 
of ototoxicity and for whom treatment with ototoxic medication is 
contraindicated.[19] 
Conclusion
Ototoxicity is a serious and common complication of treating 
life-threatening illnesses such as cancer and multidrug-resistant 
tuberculosis. Currently, prospective monitoring of patients’ hearing 
and vestibular function during treatment and instituting appropriate 
medical intervention when ototoxicity is first detected are the most 
effective strategies to prevent the debilitating effects of treatment. 
There are several areas of therapeutic development that hold 
enormous potential for eliminating the prospect of ototoxicity as an 
adverse outcome of treatment. Clinicians need to stay up to date with 
these developments.
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